“The Consortium of Rheumatology Researchers of North America, Inc. (CORRONA) is best known for its CORE Registry of over 40,000 rheumatic disorder patients followed longitudinally in the United States tracking disease and treatment trends, adverse events and co-morbidities. For more than a decade, CORRONA directors have published several reports annually from mined analyses and provide industry and other subscribers with important epidemiological data.

A subsidiary CORRONA International was initiated in 2011 to promote an international registry to study the prevalence and occurrence of targeted adverse events in patients with rheumatoid arthritis in 10 additional countries on three continents beyond North America. CORRONA International has recently successfully reached its projected enrollment on 31 December 2012 as the first phase of the international registry with the assistance of the contract research organization (CRO) AmeRuss Clinical Trials, LLC that was engaged in the final weeks of the enrollment period.

AmeRuss provides particular expertise in clinical trial conduction and a relationship network in the Russian Federation and the Commonwealth of Independent States (CIS). In our particular circumstance with regard to meeting our registry enrollment target by a fixed date in agreement with a principal subscriber, AmeRuss performed with skill and professionalism in salvaging a significant enrollment lag following our switch to AmeRuss from a multinational CRO that did not perform to our needs. We are impressed and plan to retain AmeRuss in our group of service providers for the long term project.

On the basis of our registry experience with AmeRuss to date, we recommend this organization highly for the management of similar studies.”

Joel Kremer, MD

President, CEO